Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ANI Pharmaceuticals, Inc. (ANIP : NSDQ)
 
 • Company Description   
ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN.

Number of Employees: 601

 
 • Price / Volume Information   
Yesterday's Closing Price: $30.86 Daily Weekly Monthly
20 Day Moving Average: 116,818 shares
Shares Outstanding: 17.27 (millions)
Market Capitalization: $533.02 (millions)
Beta: 1.06
52 Week High: $60.23
52 Week Low: $22.73
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -4.43% 4.65%
12 Week -17.64% -7.44%
Year To Date -33.03% -18.18%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
210 Main Street West
-
Baudette,MN 56623
USA
ph: 218-634-3500
fax: 218-634-3540
ir@anipharmaceuticals.com http://www.anipharmaceuticals.com
 
 • General Corporate Information   
Officers
Nikhil Lalwani - President; and Chief Executive Officer
Patrick D. Walsh - Chairman of the Board
Stephen P. Carey - Senior Vice President; Finance and Chief Financia
Muthusamy Shanmugam - Head of Research and Development and Chief Operati
Thomas J. Haughey - Director

Peer Information
ANI Pharmaceuticals, Inc. (CORR.)
ANI Pharmaceuticals, Inc. (RSPI)
ANI Pharmaceuticals, Inc. (CGXP)
ANI Pharmaceuticals, Inc. (BGEN)
ANI Pharmaceuticals, Inc. (GTBP)
ANI Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00182C103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/05/22
Share - Related Items
Shares Outstanding: 17.27
Most Recent Split Date: 7.00 (0.17:1)
Beta: 1.06
Market Capitalization: $533.02 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.04 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.74 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 41.52
Trailing 12 Months: 21.58
PEG Ratio: -
Price Ratios
Price/Book: 1.66
Price/Cash Flow: 6.55
Price / Sales: 2.36
EPS Growth
vs. Year Ago Period: -129.35%
vs. Previous Quarter: -171.05%
Sales Growth
vs. Year Ago Period: 18.26%
vs. Previous Quarter: 5.82%
ROE
03/31/22 - 6.66
12/31/21 - 14.10
09/30/21 - 17.80
ROA
03/31/22 - 2.81
12/31/21 - 5.94
09/30/21 - 7.43
Current Ratio
03/31/22 - 3.79
12/31/21 - 3.68
09/30/21 - 2.26
Quick Ratio
03/31/22 - 2.74
12/31/21 - 2.74
09/30/21 - 1.53
Operating Margin
03/31/22 - 7.65
12/31/21 - 15.02
09/30/21 - 16.39
Net Margin
03/31/22 - -27.78
12/31/21 - -19.71
09/30/21 - -10.40
Pre-Tax Margin
03/31/22 - -36.28
12/31/21 - -25.94
09/30/21 - -12.98
Book Value
03/31/22 - 18.60
12/31/21 - 19.73
09/30/21 - 15.01
Inventory Turnover
03/31/22 - 1.56
12/31/21 - 1.49
09/30/21 - 1.46
Debt-to-Equity
03/31/22 - 0.89
12/31/21 - 0.86
09/30/21 - 0.97
Debt-to-Capital
03/31/22 - 45.27
12/31/21 - 44.40
09/30/21 - 49.29
 

Powered by Zacks Investment Research ©